Literature DB >> 8425830

Foveal cone involvement in retinitis pigmentosa progression assessed through flash-on-flash parameters.

G Dagnelie1, R W Massof.   

Abstract

PURPOSE: To compare psychophysical Naka-Rushton parameters in retinitis pigmentosa (RP) patients and healthy controls using a flash-on-flash increment threshold paradigm, and to measure changes of these parameters with RP progression.
METHODS: Sixty-six RP patients and 10 normal subjects were tested, and their maximum response (Rmax), half-saturation intensity (sigma), and slope (n) parameters were estimated. RESULTS/
CONCLUSIONS: Rmax in RP patients is decreased significantly with respect to the range in normal controls and continues to decrease (0.024 log units/yr) with disease progression. The distribution of sigma in RP patients differs from that in normal subjects, showing lower values in general, but no progression. Small differences in parameter distributions among genetic or pathophysiologic RP subcategorizations were found, but these do not fulfill stricter statistical criteria required for multiple comparisons. Measurement noise, inherent in the flash-on-flash paradigm, exert considerable influence on the quality of the data, as was demonstrated through repeated measures and a Monte Carlo simulation.

Entities:  

Mesh:

Year:  1993        PMID: 8425830

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  2 in total

1.  Contrast response properties of magnocellular and parvocellular pathways in retinitis pigmentosa assessed by the visual evoked potential.

Authors:  Kenneth R Alexander; Aruna S Rajagopalan; William Seiple; Vance M Zemon; Gerald A Fishman
Journal:  Invest Ophthalmol Vis Sci       Date:  2005-08       Impact factor: 4.799

2.  Photoreceptor-Specific Loss of Perifoveal Temporal Contrast Sensitivity in Retinitis Pigmentosa.

Authors:  Cord Huchzermeyer; Julien Fars; Jan Kremers
Journal:  Transl Vis Sci Technol       Date:  2020-05-27       Impact factor: 3.283

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.